Shu Chin, based in Dallas, Texas, United States, is currently a VP of MIDD & Quantitative Medicine at Critical Path Institute (C-Path), bringing experience from previous roles at PTC Therapeutics, Inc., BioCryst Pharmaceuticals, Inc., Ascentage Pharma and Certara Strategic Consulting at Certara. Shu Chin holds a 2002 - 2004 Ph.D @ Yale University. With a robust skill set that includes SAS, Medical Research, NONMEM, Clinical Development, Biomedical Engineering and more, Shu Chin contributes valuable insights to the industry. Shu Chin has 4 emails and 1 mobile phone number on RocketReach.